Compare AdaptHealth Corp (AHCO) vs Nike Inc (NKE) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

Nike (NKE) trades at $43.34, down 1.7% on the day, with a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, but revenue declined to $46.31B in 2025 with net income falling to $3.22B. The stock shows strong profitability margins and a P/E of 20.64, while analysts maintain a consensus Buy rating with a $50.67 price target. Key support lies at $42, with resistance at $44.

Nike faces near-term headwinds from sluggish consumer demand and margin pressure, but its brand strength and digital direct-to-consumer strategy provide long-term upside potential. Risks include inventory challenges and economic sensitivity, yet institutional confidence remains with 48.6% analyst Buy ratings. The upcoming Q4 2026 earnings on June 30, 2026, will be critical for confirming turnaround progress.